$CRD-A

Bart Andrew John sold $180K of CRD-A

Bart Andrew John (Executive Vice President) sold 13,623 shares of CRAWFORD & CO (CRD-A) at an average of $13.24 ($13.17–$13.45, $0.18M total) across 2 trades over 2026-08-14 to 2026-08-17.

Original reporting
SEC EDGAR · Bart Andrew John
Published Aug 18, 2026, 2:26 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Aug 18, 2026, 4:02 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
AlphAI market briefInsider activity
Primary signal
$CRD-A
Neutral
medium confidence
Mentioned
$CRD-A
Relevance
4/10
AlphAI data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$CRD-ANeutralLow
01

Why it matters

This adds incremental sentiment information (insider reduced direct holdings) but does not change the company’s fundamentals based on the provided text.

02

Market read

Traders may monitor for follow-on insider activity, but the disclosure alone is unlikely to drive a major repricing without accompanying fundamental catalysts.

03

What to watch

The article provides sale price range and post-sale holdings but no context on total compensation, tax events, or whether additional sales occurred outside the reported window.

Relevance 4/10Novelty 3/10Timing: filed 2026-08-18, covering sales dated 2026-08-14 to 2026-08-17

Background

The article is an SEC Form 4 insider transaction disclosure for Crawford & Co, reporting an officer’s open-market sale.

Company-level read

Ticker impact

$CRD-ANeutralMedium confidence
Context

Crawford & Co executive vice president sold $180,356 of CRD-A shares in two open-market trades, per a fresh SEC Form 4 filing.

Expected impact

Low likelihood of sustained price impact; any reaction is likely limited to short-term sentiment.

Evidence & confidence

The filing is a primary-source Form 4 showing an open-market sale by an officer, but it does not include earnings, guidance, or operational/regulatory developments.

Market effects

No sector-wide signal; this is company-specific insider transaction data.

None indicated.

None indicated.

Counterpoint

Insider sales can be planned for diversification or liquidity needs; absence of a 10b5-1 plan does not necessarily imply negative expectations.

Key entities

  • Crawford & Co

    Subject of the Form 4 insider transaction disclosure, ticker shown as CRD-A in the filing extract.

  • Bart Andrew John

    Executive Vice President who sold 13,623 shares in two open-market trades.

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

Related articles

$CRD-AMedAI 8/10

Crawford & Company Reports 2026 Third Quarter Results

Crawford & Company (CRD-A, CRD-B) reported Q3 2026 revenues of $321.6M, down slightly from $322.2M in Q3 2025. Net income rose to $15.0M ($0.31 per share) from $12.4M ($0.25 per share). International operations drove improved performance, while U.S. segments saw declines. The CEO highlighted progress in cost management and client relationships, but expects fourth-quarter pressure from lower claims frequency.

$CRD-AMed

CRAWFORD & COMPANY REPORTS 2026 SECOND QUARTER RESULTS

CRAWFORD & CO (CRD-A) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 Crawford & Company® 5335 Triangle Parkway Peachtree Corners, GA 30092 FOR IMMEDIATE RELEASE CRAWFORD & COMPANY REPORTS 2026 SECOND QUARTER RESULTS Strong Earnings Growth Driven by International Operations and Broadspire Quarterly Dividend Increases to $0.08 per Share

$ASPEMedAI 8/10

ARCH Venture Fund X, L.P. (CRANDELL KEITH, Burow Kristina) purchased $18.0M of ASPE (indirect holdings)

ARCH Venture Fund X, L.P. purchased 1,200,000 indirectly-held shares of Aspen Neuroscience, Inc. (ASPE) at $15.00 ($18.00M total) on 2026-11-02. Filed jointly with ARCH Venture Fund X Overage, L.P. (10% owner), ARCH Venture Partners X, L.P. (10% owner), ARCH Venture Partners X Overage, L.P. (10% owner), ARCH Venture Partners X, LLC (10% owner), CRANDELL KEITH (10% owner), Burow Kristina (10% owner), GILLIS STEVEN (10% owner) and NELSEN ROBERT (10% owner).

$ASPELow

ARCH Venture Fund X, L.P. (CRANDELL KEITH, Burow Kristina) purchased $2.0M of ASPE

ARCH Venture Fund X, L.P. purchased 133,333 shares of Aspen Neuroscience, Inc. (ASPE) at $15.00 ($2.00M total) across 2 trades on 2026-11-02. Filed jointly with ARCH Venture Fund X Overage, L.P. (10% owner), ARCH Venture Partners X, L.P. (10% owner), ARCH Venture Partners X Overage, L.P. (10% owner), ARCH Venture Partners X, LLC (10% owner), CRANDELL KEITH (10% owner), Burow Kristina (10% owner), GILLIS STEVEN (10% owner) and NELSEN ROBERT (10% owner).